Oragenics Inc (NYSEAMERICAN:OGEN) Short Interest Update

Oragenics Inc (NYSEAMERICAN:OGEN) was the recipient of a significant growth in short interest in the month of December. As of December 29th, there was short interest totalling 286,908 shares, a growth of 155.3% from the December 15th total of 112,379 shares. Based on an average daily volume of 352,168 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.8% of the shares of the company are sold short.

Oragenics (OGEN) opened at $0.18 on Friday. Oragenics has a 12 month low of $0.06 and a 12 month high of $0.85. The stock has a market capitalization of $8.68, a price-to-earnings ratio of -1.10 and a beta of 1.32.

Shares of Oragenics are set to reverse split on Monday, January 22nd. The 1-10 reverse split was announced on Monday, January 8th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 19th.

Separately, ValuEngine raised Oragenics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, September 26th.

COPYRIGHT VIOLATION WARNING: “Oragenics Inc (NYSEAMERICAN:OGEN) Short Interest Update” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2018/01/20/oragenics-inc-ogen-short-interest-up-155-3-in-december.html.

About Oragenics

Oragenics, Inc develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering.

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply